Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases. The company’s lead program in BAG3-associated dilated cardiomyopathy (DCM) uses gene transfer technology to address the monogenic cause of this severe form of heart failure. Renovacor’s vision is to bring life-changing therapies to patients living with serious genetic cardiovascular and related diseases, by developing medicines that target the underlying cause of disease and provide a transformative benefit and significant improvement to quality of life.
Company Details
- Employees
- 7
- Founded
- 2019
- Address
- The Monogenic Cause Of This Severe Form Of Heart Failure. Renovacor’s Vision Is To Bring Life-Changing Therapies To Patients Living With Serious Genetic Cardiovascular And Related Diseases
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://renovacor.com/
- Keywords
- Cardiology and Gene Therapy.
Renovacor Questions
Renovacor's website is https://renovacor.com/
Renovacor's LinkedIn profile is https://www.linkedin.com/company/renovacor
Renovacor has
7 employees.
View email and phone details for 7
employees at Renovacor.
Renovacor's industry is
Biotechnology Research
Renovacor's top competitors are
Militia Hill Ventures,
Haya Therapeutics,
Rocket Pharmaceuticals,
Lexeo Therapeutics,
Swanbio Therapeutics,
Cellgebra,
Cellclar Cic,
Spirovant Sciences, Inc.,
Syvento Biotech,
Voyager Therapeutics, Inc..
Renovacor's categories are Biotechnology Research
Renovacor's founding year is 2019
